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Abstract
The aim of the present study was to investigate whether the survival-improving effect of atorvastatin in sepsis is
accompanied by a reduction in tissue activation of inflammatory pathways and, in parallel, an improvement in tissue insulin
signaling in rats. Diffuse sepsis was induced by cecal ligation and puncture surgery (CLP) in male Wistar rats. Serum glucose
and inflammatory cytokines levels were assessed 24 h after CLP. The effect of atorvastatin on survival of septic animals was
investigated in parallel with insulin signaling and its modulators in liver, muscle and adipose tissue. Atorvastatin improves
survival in septic rats and this improvement is accompanied by a marked improvement in insulin sensitivity, characterized
by an increase in glucose disappearance rate during the insulin tolerance test. Sepsis induced an increase in the expression/
activation of TLR4 and its downstream signaling JNK and IKK/NF-kB activation, and blunted insulin-induced insulin signaling
in liver, muscle and adipose tissue; atorvastatin reversed all these alterations in parallel with a decrease in circulating levels
of TNF-a and IL-6. In summary, this study demonstrates that atorvastatin treatment increased survival, with a significant
effect upon insulin sensitivity, improving insulin signaling in peripheral tissues of rats during peritoneal-induced sepsis. The
effect of atorvastatin on the suppression of the TLR-dependent inflammatory pathway may play a central role in regulation
of insulin signaling and survival in sepsis insult.
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Introduction
Sepsis is one of the most prevalent diseases and one of the main
causes of death among hospitalized patients [1]. During the onset
of sepsis, the inflammatory system becomes hyperactive, leading to
an over-production of pro-inflammatory mediators [2], which
contribute to septic shock, multiple organ failure, and death.
Hyperglycemia and insulin resistance occur during sepsis, as a
consequence of the metabolic effects of stress hormone and
cytokine production [3,4,5,6]. Although in the past years there has
been considerable progress in our understanding of the patholog-
ical pathways that contribute to sepsis and septic shock,
pharmacological interventions are currently limited to insulin
and activated protein C [7]. Insulin is infused in septic patients
with hyperglycemia to normalize glucose levels [7,8], and it is
hypothesized that this reduction in glycaemia is associated with
decreased inflammation and endothelial cell damage [4,5,6,9,10].
Conversely, results from animal studies indicate that insulin may
have direct anti-inflammatory effects, independent of its effect on
hyperglycemia [11,12,13]. However, the mechanism by which
insulin reduces inflammation in the absence of hyperglycemia is
unknown. Recent data demonstrate that insulin reduces inflam-
mation by activating anti-inflammatory signaling pathways, such
as the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)
pathway. Moreover, it is now well established that this pathway
negatively regulates LPS-induced signaling and pro-inflammatory
cytokine production [14,15,16,17] and activation of PI3K/Akt
pathway enhanced survival, whereas inhibition of PI3K reduced
survival of endotoxemic mice [15,18]. In animal models of sepsis,
there is a down regulation of the PI3K/Akt pathway that may be
the consequence of TLR4 activation and downstream in activation
of well established inducers of insulin resistance as JNK, IKK-b
and iNOS. Taken together, these data indicate that this insulin
signaling pathway, which is reduced in sepsis, may be activated by
insulin to mediate the protective effects of insulin in endotoxemia.
However, insulin-induced hypoglycemia may counteract the
beneficial effects of aggressive insulin therapy in patients with
severe sepsis [19].
These data suggest that the ideal drug to improve survival in
sepsis should reduce the over-reaction of the inflammatory
response and, in parallel, should improve insulin signaling in the
PI3K/Akt pathway, without inducing hypoglycemia. Recently,
knowledge about statins, a class of powerful hypolipemic drugs
with pleiotropic effects, such as anti-inflammatory, antioxidative,
immunomodulatory properties, suggest that these agents may offer
a novel therapeutic or prophylactic strategy to sepsis [1,2,20].
Relevant epidemiological evidence suggests that use of statins may
decrease progression to severe sepsis [21], reduce mortality rates
[22,23,24,25,26,27,28,29] and reduce the risk of infections and
infection-related complications [30,31,32,33,34]. However, the
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well established. The aim of the present study was to investigate
whether the ability of atorvastatin to improve survival in sepsis is
accompanied by a reduction in tissue activation of inflammatory
pathways and, in parallel, an improvement in tissue insulin
signaling.
Results
Atorvastatin Improves Survival and Protects Against
Insulin Resistance in Septic Rats
In the first part of the study, we examined the effect of
atorvastatin on the survival curve in animals in which sepsis was
induced via CLP. Atorvastatin (10 mg/kg) or placebo was
administered by gavage 3 h after surgery or the procedure in
sham-operated animals. No deaths occurred in the sham-operated
animals, whether or not they had been treated with atorvastatin.
The survival curves for rats, in which CLP was performed, are
shown in Figure 1A and clearly delineate the benefit sustained
from atorvastatin treatment due to improved survival (P,0.0001).
As shown in Fig. 1B and 1C, septic animals were more insulin
resistant than sham rats; fasting plasma glucose and insulin levels
were higher in septic rats than in the control group, and
atorvastatin treatment reduced these levels. As depicted by
Fig. 1D the plasma glucose disappearance rates measured during
the insulin tolerance test (Kitt) were lower in septic animals and
atorvastatin treatment reversed these alterations. This improve-
ment is also suggested by the HOMA-IR index, calculated from
fasting glycaemia and insulinemia, which is increased in septic
animals and significantly decreased in those treated with
atorvastatin (Fig. 1E). Atorvastatin treatment had no effect on
insulin tolerance in the sham group. Taken together, these data
suggest that atorvastatin reversed the sepsis-induced insulin
resistance.
Effect of Atorvastatin on Serum Levels of IL-6 and TNF-a
The serum levels of IL-6 and TNF-a were also higher in septic
animals compared with sham-operated rats. After atorvastatin
treatment there was a significant decrease in IL-6 (Fig. 1F) and
TNF-a (Fig. 1G) circulating levels.
Atorvastatin Improves Insulin Signaling in Liver, Muscle
and Adipose Tissue of Septic Animals
In the sepsis group, insulin-induced IR and IRS-1 tyrosine
phosphorylation were decreased in liver, muscle and adipose tissue
when compared with sham rats and these alterations were reversed
by atorvastatin (Fig. 2A–F). In parallel, there was a decrease in
insulin-induced Akt serine phosphorylation in the liver, muscle
and adipose tissue of septic animals when compared with sham
rats and atorvastatin was able to reverse these reductions in Akt
phosphorylation (Fig. 2G–I). The modulation in IR, IRS-1 and
Akt phosphorylation, induced by sepsis and reversed by atorvas-
tatin, was independent of changes in tissue protein expression
(Fig. 2A–I). The protein concentration of IR, IRS-1, and Akt did
not change between the groups. Equal protein loading in the gels
was confirmed by reblotting the membranes with an anti-b-actin
antibody (lower panels).
Atorvastatin Attenuates Sepsis-Induced Inflammatory
Changes
Toll-like receptor 4 (TLR4) is a transmembrane receptor that
participates in pathogen recognition during the inflammatory
response, and leads to cytokine and other immune-related gene
expression [35,36]. During sepsis, the activation of TLR4 signaling
induces upregulation of intracellular inflammatory pathways, such
as the IkB kinase b (IKK-b)/nuclear factor kappa B (NFk-B)
pathway.
Next, we examined the immunomodulatory effects of atorvas-
tatin on TLR4 activation in liver, muscle and adipose tissue of
septic animals. Fig. 3 shows that sepsis induced TLR4 protein
levels and activation, as demonstrated by an increase in TLR4/
MyD88 interaction in the three tissues investigated, and
atorvastatin reduced this early step of TLR4 activation and also
TLR4 expression (Fig. 3A–C).
Downstream of TLR4 activation, we examined the IKK–NF-
kB pathway, an important regulator of inflammation and insulin
resistance. The main function of the IKK complex is the activation
of NFkB through phosphorylation and degradation of IkBa
[37,38]. NFkB activity was monitored using IKKb and IkBa
phosphorylation, as described previously [39]. As expected, IKKb
and IkBa phosphorylation were increased in liver, muscle and
adipose tissue of septic animals and atorvastatin decreased these
phosphorylations in the tissues investigated (Fig. 3D–I).
JNK activation was determined by monitoring phosphorylation
of JNK (Thr183 and Tyr185) and c-Jun (Ser63), which is a
substrate of JNK. JNK phosphorylation in liver, muscle and
adipose tissue were increased in septic animals and atorvastatin
induced a downmodulation in the phosphorylation of this serine
kinase (Fig. 4A–C). Consistent with JNK activation, c-Jun
phosphorylation was induced by sepsis and reversed by atorvas-
tatin in the tissues investigated (Fig. 4D–F).
We also investigated Ser307 phosphorylation of IRS-1 in liver,
muscle, and adipose tissue in the four groups of rats. Ser307
phosphorylation was induced by sepsis in the three tissues and the
treatment with atorvastatin reversed this alteration (Fig. 4G–I).
NFkB nuclear subunit p50 expression was determined in nuclear
extracts and we found an increase in this subunit in nuclear
extracts of septic animals, but there was a clear decrease in the
three tissues after atorvastatin treatment (Fig. 5A–C). The tissue
expressions of iNOS (Fig. 5D–F) and IL-6 (Fig. 5G–I) were higher
in liver, muscle and adipose tissue of septic rats that received
saline, and were significantly reduced by atorvastatin treatment.
Previous studies have shown that sepsis is also characterized by
endoplasmic reticulum stress. It is clear that ER stress can also
induce activation of JNK and IKKb. We then investigated the
effect of sepsis (treated or not with atorvastatin) on proteins that
reflect ER stress. Our data showed that sepsis induced ER-stress,
as determined by the increased phosphorylation of the ER
membrane kinase, PERK (PKR-like endoplasmic reticulum
kinase) and its substrate (Fig. 6A–C), eIF2a (eukaryotic translation
initiation factor 2a) (Fig. 6D–F) and increased the expression of
ATF6a (Fig. 6G–I). Treatment with atorvastatin significantly
reduced the expression of all markers of ER-stress. (Fig. 6A and D)
Discussion
In sepsis, the acute immune response is organized and executed
by innate immunity. This response starts with sensing of danger by
pattern-recognition receptors on the immune competent cells and
endothelium. The pattern-recognition receptors, mainly toll-like
receptor (TLR), are also activated in other tissues such as liver,
muscle and adipose tissue [40]. The sensed danger signals, through
specific signaling pathways, activate transcription factors and gene
regulatory systems, which up-regulate the expression of pro-
inflammatory mediators. However, the over-reaction of this pro-
inflammatory response has an important role in the development
of multiple organ failure and death. The combinations of the
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PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14232Figure 1. Effect of atorvastatin on survival in CLP sepsis model. Male Wistars rats, 8 weeks old, were given saline (Sepsis/Sal, n=20) or
atorvastatin 10 mg/kg (Sepsis/Ator, n=20), 3 h and once a day after CLP. Survival of the rats was monitored at intervals of 12 h for 15 days. The
overall difference in survival rate between the groups with and without atorvastatin was significant (P,0.0001) (A). Fasting blood glucose (B). Fasting
insulin levels (C). Glucose disappearance rate (D). HOMA-IR index (E). Serum levels of TNF-a (F) and IL-6 (G). Data are presented as means and S.E. of six
to eight rats per group. *P,0.05 (Sepsis saline vs. all others groups).
doi:10.1371/journal.pone.0014232.g001
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PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14232Figure 2. Effects of atorvastatin treatment on insulin signaling in the CLP rat. Representative blots show insulin-induced tyrosine
phosphorylation of Insulin Receptor b (IRb) in liver (A), muscle (B) and adipose (C) of sham and septic rats. Total protein expression of IRb (A–C, lower
panels). Insulin-induced tyrosine phosphorylation of Insulin Receptor Substrate 1 (IRS1) in liver (D), muscle (E) and adipose tissue (F) of sham and
septic rats. Total protein expression of IRS1 (D–F, lower panels). Insulin-induced serine phosphorylation of Akt in liver (G), muscle (H) and adipose (I) of
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the cytokine storm of sepsis have an important role in insulin
resistance. In this regard, tissue insulin resistance may be used as
an important indicator of the resultant actions of pattern
recognition receptors and the induction of the pro-inflammatory
cytokines, being a tissue marker of severity of sepsis, before organ
failure. In addition, this insulin resistance may also aggravate
sepsis, as previously described [3,4,41]. In this regard, we believe
that the evaluation of insulin signaling pathway through PI3K/Akt
in liver, muscle and adipose tissue may be important indicators of
this over-reaction at the tissue level, and the improvement in this
signaling pathway, induced by some treatments, in parallel with a
decrease in tissue inflammation, may predict the effectiveness of
this treatment.
In the present study, we demonstrated that atorvastatin
improves survival in septic rats, decreases circulating inflammatory
cytokines and improves insulin resistance, in parallel with a
decrease in TLR4 signaling and an improvement in insulin
signaling in liver, muscle and adipose tissue. The improvement in
survival of septic animals when using statins has been previously
described, and was related to a complete preservation of cardiac
function and hemodynamic status and also a reversion of increased
monocyte adhesion to the endothelium, all of which were altered
in septic animals without treatment [42,43].
Our data show that atorvastatin, administered 3 hours after the
induction of sepsis, is able to improve the survival curve,
attenuating higher levels of IL-6 and TNF-a and reduce insulin
resistance, as demonstrated during the insulin tolerance test. In
septic animals, insulin resistance was accompanied by a reduction
in insulin-induced IR, IRS-1 tyrosine phosphorylation and in
insulin-induced Akt phosphorylation, in liver, muscle and adipose
tissue. Since Akt has a critical role in protection from apoptosis, it
is possible that the reduced insulin signaling through this IRSs/
PI3K/Akt pathway, in sepsis, may contribute to multi-organ
failure by preventing or delaying apoptosis [14,15,44]. In this
study, we demonstrate that pretreatment with atorvastatin inhibits
sepsis-induced insulin resistance by improving insulin signaling via
the IR–IRS-1–Akt pathway in target tissues. This restoration of
insulin signaling in these tissues would allow the animal to have an
appropriate control of hepatic glucose output and of the peripheral
glucose uptake and storage. In addition, skeletal muscle and
adipose tissue contribute to IL-6 expression during sepsis
[45,46,47], and since the anti-inflammatory effect of insulin is
mediated through the PI3K pathway [14,15,18], we can speculate
that the restoration of this pathway in the insulin-dependent
tissues, induced by atorvastatin in septic animals, may have also
contributed to the anti-inflammatory effect of this drug.
During the past ten years, accumulating evidence shows a clear
molecular interaction between metabolic and immune signaling
systems in different situations of insulin resistance [40,48,49]. We
and others have previously demonstrated that TLR4 signaling is
activated in diet induced obesity (DIO), and that this activation
culminates in an increase in the activation of downstream effectors
such as IKKb, JNK and iNOS, which have critical roles in insulin
resistance [40]. In septic animals, there was an increase in TLR4
activation and also in downstream effectors that may have an
important role in the insulin resistance of these animals [50]. Our
data show that atorvastatin decreases TLR4 expression/activa-
tion, a modulation that might have a role in the attenuated
expression of inflammatory mediators in response to a septic insult.
The reduction in TLR4 expression/activation, observed in our
study, is in accordance with a previous study that also observed
this effect on TLR4 expression/activation with different statins
and cell types [51].
The immune modulator activity of atorvastatin was evident
downstream from TLR4, at the level of IKK/IkB/NF-kB
pathway activation. Atorvastatin induced a significant decrease
in IKK phosphorylation and, as expected, an increase in IkB
phosphorylation, suggesting a deactivation of this pathway. NF-kB
has been documented to play a major role in sepsis induced
inflammatory cytokine expression [52,53,54]. Our findings suggest
that NF-kB, which is normally translocated from the cytoplasm to
the nucleus after sepsis insult, was strongly inhibited by
atorvastatin in the three target tissues studied. This result suggests
that the atorvastatin-mediated inhibition of cytokine production
may be the consequence of the modulation of the IKK/IkB/NF-
kB pathway by this drug.
The activation of NF-kB with its translocation to the nucleus is
able to induce the increase in TNF-a, IL-6 and in iNOS in septic
animals [37,38,55]. TNF-a is one of the crucial pro-inflammatory
cytokines; however, when over produced by deregulation or
persistent infection, TNF-a may induce septic shock and
contributes to insulin resistance, and its levels are drastically
elevated in a number of forms of human sepsis, in turn correlating
with increased mortality [56]. Specifically, iNOS and IL-6 have
been shown to be produced early in the response and have been
suggested to play critical roles in driving physiological/patholog-
ical responses that lead to septic shock [57]. We further
investigated the effects of atorvastatin on the production of these
inflammatory proteins in tissues and serum of septic rats. In
accordance with previous data, atorvastatin treatment inhibited
iNOS, TNF-a and IL-6 expression in the muscle, liver and adipose
tissues of septic rats, and also the circulating levels of TNF-a and
IL-6. [58]. Previous studies have demonstrated that skeletal muscle
and adipose tissue contribute to IL-6 production during endotox-
emia [45,46,47], and the anti-inflammatory effects of atorvastatin
on IL-6 production in sepsis may be the result of the direct
activation of PI3K pathway in these tissues. The atorvastatin-
mediated reduction of these negative modulators of insulin
signaling may have an important role in the improvement of
insulin signaling observed in the three tissues of septic animals.
Another TLR4 downstream pathway by which atorvastatin
could attenuate the inflammatory response induced by sepsis is
through JNK, a serine kinase that is responsible for activation of
the inflammatory pathway by phosphorylation of the c-Jun and
ATF2 transcription factors [59,60]. Several studies suggest that
JNK contributes to insulin resistance by phosphorylating IRS-1 at
serine 307, and this phosphorylation leads to inhibition of IRS-1
function [26,27,30,33,61,62,63,64], although this has very recently
been questioned [65]. Here, we observed that sepsis led to serine
phosphorylation of IRS-1 and that atorvastatin reversed this
phenomenon in three target tissues, in parallel with a reduction in
JNK activity. Our data showing that atorvastatin inhibits JNK
phosphorylation/activation in septic rats indicate that the
beneficial effect of this drug in improving survival and reducing
insulin resistance is mediated by different pathways.
Besides being activated by TLR4, JNK activity is induced in
different pathophysiological states including infection, inflamma-
sham and septic rats. Insulin-induced threonine phosphorylation and total protein expression of Akt (G–I, lower panels). In this case, blots were
stripped and reprobed with b-actin (A–I, lower panels) to confirm equal loading of proteins. Data are presented as means +/2 S.E.M from 6–8 rats per
group. *P,0.05 (Sepsis/Sal vs. all others groups). IB, immunoblot; CLT: Sham/Saline; ShT: Sham/Atorvastatin; SAL: saline; ATOR: atorvastatin.
doi:10.1371/journal.pone.0014232.g002
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14232Figure 3. To evaluate the association of TLR4 with MyD88, immunoprecipitations were performed with MyD88 antibody followed
by immunoblotting with TLR4 specific antibody. Representative blots show TLR4 activation (upper panels) and expression (lower panels) in
liver (A), muscle (B) and adipose tissue (C) of sham and septic rats. IKKb phosphorylation in liver (D), muscle (E) and adipose (F) of sham and septic
rats. Total protein expression of IKKb (D–F, lower panels). Phosphorylation of IkBa in liver (G), muscle (H) and adipose (I) of sham and septic rats. Data
are presented as means 6S.E.M from 6–8 rats per group. *P,0.05 (Sepsis/Sal vs. all other groups); **P,0.001 (Sepsis/Sal vs. control); #P,0.05
(Sepsis/Sal vs. Sepsis/Ator). IB, immunoblot; CLT: Sham/Saline; ShT: Sham/Atorvastatin; SAL: saline; ATOR: atorvastatin.
doi:10.1371/journal.pone.0014232.g003
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14232Figure 4. Representative blots show the JNK phosphorylation in liver (A), muscle (B) and adipose tissue (C) of sham and septic rats
(upper panels). Total protein expression of JNK (A–C, lower panels). Phosphorylation of c-jun in liver (D), muscle (E) and adipose tissue (F) of sham
and septic rats. Serine 307 Phosphorylation of IRS1 in liver (G), muscle (H) and adipose tissue (I) of sham and septic rats (upper panels). Total protein
expression of IRS-1 (G–I, lower panels). Data are presented as means 6 S.E.M from 6–8 rats per group. *P,0.05 (Sepsis/Sal vs. all others groups);
**P,0.001 (Sepsis/Sal vs. control); #P,0.05 (Sepsis/Sal vs. Sepsis/Ator). IB, immunoblot; CLT: Sham/Saline; ShT: Sham/Atorvastatin; SAL: saline; ATOR:
atorvastatin.
doi:10.1371/journal.pone.0014232.g004
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14232Figure 5. Representative blots show the NFkB activation in nuclear fractions of liver (A), muscle (B) and adipose tissue (C) of sham
and septic rats. In this case blots were stripped and reprobed with actin (A–C, lower panels) to confirm equal loading of proteins. Tissue levels of
iNOS (D–F) and IL-6 (G–I) expression in liver, muscle and adipose tissue of sham and septic rats. Data are presented as means 6 S.E.M from 6–8 rats
per group. *P,0.05 (Sepsis/Sal vs. all others groups); **P,0.001 (Sepsis/Sal vs. control); #P,0.05 (Sepsis/Sal vs. Sepsis/Ator). IB, immunoblot; CLT:
Sham/Saline; ShT: Sham/Atorvastatin; SAL: saline; ATOR: atorvastatin.
doi:10.1371/journal.pone.0014232.g005
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14232Figure 6. Representative blots show the PERK phosphorylation in liver (A), muscle (B) and adipose tissue (C) of sham and septic
rats. eIF2a phosphorylation (D–F) and ATF6 (G–I) expression in liver, muscle and adipose tissue of sham and septic rats. In this case, blots were
stripped and reprobed with actin (A–I, lower panels) to confirm equal loading of proteins. Data are presented as means 6 S.E.M from 6–8 rats per
group. *P,0.05 (Sepsis/Sal vs. all others groups); #P,0.05 (Sepsis/Sal vs. Sepsis/Ator). IB, immunoblot; CLT: Sham/Saline; ShT: Sham/Atorvastatin;
SAL: saline; ATOR: atorvastatin.
doi:10.1371/journal.pone.0014232.g006
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stress [66,67,68]. The cellular response to ER stress, referred to as
UPR, results in the activation of three linked signal transduction
pathways emanating from three principle ER stress sensors:
IRE1a, double-stranded RNA–dependent protein kinase–like
kinase (PERK) and ATF6a [49,69]. Mechanistically, activation
of the UPR contributes to the decrease in insulin sensitivity
through IRE1a-dependent activation of c-Jun N-terminal kinase
(JNK) [70,71]. Recently, it was demonstrated that statins are able
to prevent ER stress [72]. In the present study, we confirm this
finding by showing that atorvastatin strongly inhibited phosphor-
ylation of IRE1a and PERK and ATF6a expression, suggesting
that this drug can attenuate the ER-stress induced by sepsis.
Overall, our data demonstrate that atorvastatin exerts direct
regulatory effects on TLR4 expression/activation in an animal
model of sepsis that influences TLR4 signaling. Atorvastatin
reduces TLR4 surface expression on liver, muscle and adipode
tissues, causing downregulation of proinflammatory pathways such
as IKK and JNK, leading to a decrease in NF-kB activation and
cytokine expression. In addition, atorvastatin also decreases ER
stress and, consequently, the activation of JNK and IKK. Thus, we
suggest that the effects of atorvastatin on TLR4 expression/
activation and on ER stress are mechanistically relevant to
improve the sepsis-induced insulin resistance. There are several
potential limitations to the present study.
To date, pharmacological interventions in sepsis have usually
been limited to insulin and Protein C [7]. The beneficial effects of
activated protein C are partially independent from its anticoag-
ulant activity and may be related to anti-inflammatory and anti-
apoptotic effects, but its effect on insulin signaling is unknown.
Insulin has anti-inflammatory effects [11,12,13,19], which are
dependent on PI3K signaling, and the infusion of this hormone
induces the PI3K/Akt pathway. However, the beneficial effect of
insulin may be overcome by hypoglycemia. It is important to
mention that, in sepsis, many inflammatory pathways are activated
in parallel with a reduction in the PI3K/Akt pathway, thus,
merely blocking a single component of the inflammatory pathways
or inducing the activation of PI3K may be insufficient to arrest the
process. In this regard, our data show that atorvastatin is able to
modulate entire families of inflammatory mediators, associated
with a clear improvement in tissue insulin signaling and in insulin
sensitivity, suggesting mechanisms for its efficiency in sepsis.
Additionally, our data may suggest that the investigation of drugs
in sepsis should take into account tissue measurements of
inflammatory pathways and insulin signaling, or other early tissue
markers that indicate the severity of sepsis.
In summary, this study demonstrated that treatment with
atorvastatin increased survival with a significant effect upon insulin
sensitivity, improving insulin signaling in peripheral tissues of the
rat during peritoneal-induced sepsis. This drug reduces TLR4
activation, in association with downstream JNK and IKK/NF-kB
activation and downregulated the serum levels of cytokine release.
The effect of atorvastatin on TLR-dependent inflammatory
pathway suppression may play a central role in the regulation of
insulin signaling and survival following the sepsis insult.
Materials and Methods
Materials
Anti-IR-b (a-IR), anti-IRS-1, anti-Akt, anti-p-JNK, anti-iNOS,
anti-NFkB, anti-IL6, anti-TLR4, anti-IKKb, anti-pIKKb, anti-
pIkBa, anti-MyD88, anti-p-cjun, anti-pJNK, anti-pPERK anti-
PERK, anti-ATF6a and anti-IRE1a antibodies were from Santa
Cruz Technology (Santa Cruz, CA, USA). Anti-pAkt was from
Cell Signaling Technology (Beverly, MA, USA). Anti-phospho-
IRS-1
ser307 was obtained from Upstate Biotechnology, Inc. (Lake
Placid, NY, USA). Anti-peIF2a was from Abcam (Cambridge,
MA, USA). Atorvastatin was obtained from Pfizer (Loughbeg,
County Cork, Ireland). Human recombinant insulin was from Eli
Lilly and Co. (Indianapolis, Indiana, USA). Routine reagents were
purchased from Sigma Chemical Co. (St. Louis, MO, USA),
unless specified elsewhere.
Animal Care and Experimental Procedures
All experiments were approved by the Ethics Committee at the
University of Campinas, CEEA/Unicamp 1267-1. Male Wistar-
Hannover (8 wks old) were maintained in a room with 12-hour
day/night cycles and room temperature of 21uC, with food and
water ad libitum. Wistar rats were randomly divided into four
groups; atorvastatin-treated sepsis (Sepsis/Ator), saline-treated
sepsis (Sepsis/Sal), atorvastatin-treated sham (Sham), and saline-
treated sham (Control).
Cecal ligation and puncture (CLP) was performed, as previously
described [73], and is a commonly-used surgical technique in
rodents and thought to be a clinically relevant animal model of
sepsis. Anesthesia was induced by IP administration of ketamine
(80 mg/kg BW) and xylazine (15 mg/kg). Through a 1-cm
abdominal midline incision, the cecum was ligated below the
ileocecal valve with careful attention to avoid obstruction of the
ileum or colon. The cecum was subjected to a four ‘‘through-and-
through’’ perforations (20-gauge needle). The abdominal incision
was closed in layers. Sham-operated rat underwent the same
procedure, except for ligation and perforation of the cecum. All
procedures were performed under sterile conditions. Animals were
allowed to recover and were observed twice a day. Three hours
after the induction of sepsis and every 24 hours rats received
atorvastatin (10 mg/kg) or an equivalent volume of saline by oral
gavage. The dose of atorvastatin was chosen on the basis of
previous findings [74] and was consistent with the maximum
human dose (1.1 mg/kg per day), and the higher metabolic rate of
the drug in rodents [75].
Homeostasis Model Assessment
Insulin resistance was assessed from fasting insulin and glucose
levels, using the previously validated homeostasis model of
assessment (HOMA-IR), as previously described [76,77].
HOMA-IR was calculated by the formula: fasting plasma glucose
(mmol/l) x fasting plasma insulin (mU/l)/22.5. Fasting blood
glucose was measured by the glucose oxidase method. Plasma
insulin was assayed using commercial rat-specific radioimmuno-
assay kits (Linco Research Inc, St. Louis, MO, USA).
Insulin tolerance Test (ITT)
The insulin tolerance test (ITT) was performed on these rats at
24 hours after sepsis, as previously described [78]. Insulin (1.5 U/kg)
wasadministered by i.p. injectionand blood sampleswere collected at
0, 5, 10, 15, 20, 25, and 30 min to determine serum glucose. The
constant rate for glucose disappearance (Kitt) was calculated using the
formula 0.693/t1/2. Glucose t1/2 was calculated from the slope of
the least-squares analysis of plasma glucose concentrations during the
linear decay phase [76].
Cytokines Assays
IL-6 and TNF-a were determined using commercially available
ELISA kits (Pierce Biotechnology Inc., Rockford, IL, USA),
following the instructions of the manufacturer.
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Immunoblotting
Rats were anaesthetized by intraperitoneal injection of sodium
thiopental and were used 10–15 min later, i.e. as soon as
anesthesia was assured by the loss of pedal and corneal reflexes.
Five minutes after saline (0.2 ml) or insulin injection (3.8 U/Kg
ip), liver, muscle and adipose tissue were removed, minced
coarsely and homogenized immediately in extraction buffer, as
described elsewhere. Extracts were used for immunoprecipitation
with MyD88 and Protein A-Sepharose 6MB (Pharmacia, Uppsala,
Sweden). NFkB p50 activation was determined in nuclear extracts
from liver, muscle and adipose tissue, as previously described [79].
The precipitated proteins and/or whole tissue extracts were
subjected to SDS-PAGE and immunoblotting, as previously
described [40,78].
Statistical Analysis
The overall difference in survival rate was determined by the
Kaplan–Meier test followed by log–rank test. Specific protein
bands present in the blots were quantified by digital densitometry
(ScionCorp Inc., Frederick, MD, USA). Means 6 S.E.M. obtained
from densitometric scans, area measurements, and the values for
blood IL-6, TNF-a and glucose were compared by ANOVA with
post hoc test (Bonferroni). A P value of p,0.05 was accepted as
statistically significant.
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